Cibus, Inc. (NASDAQ:CBUS) Sees Significant Increase in Short Interest

Cibus, Inc. (NASDAQ:CBUS) saw a large increase in short interest in May. As of May 31st, there was short interest totalling 659,100 shares, an increase of 8.0% from the May 15th total of 610,400 shares. Currently, 4.6% of the shares of the stock are sold short. Based on an average daily trading volume, of 90,900 shares, the short-interest ratio is currently 7.3 days.

Institutional Trading of Cibus

Several hedge funds have recently modified their holdings of the stock. FMR LLC raised its stake in shares of Cibus by 0.4% in the third quarter. FMR LLC now owns 2,496,152 shares of the company’s stock valued at $45,480,000 after acquiring an additional 8,763 shares in the last quarter. Vanguard Group Inc. increased its holdings in Cibus by 3.7% in the first quarter. Vanguard Group Inc. now owns 721,945 shares of the company’s stock valued at $16,215,000 after buying an additional 26,017 shares during the last quarter. Indie Asset Partners LLC increased its holdings in Cibus by 30.1% in the fourth quarter. Indie Asset Partners LLC now owns 16,929 shares of the company’s stock valued at $332,000 after buying an additional 3,921 shares during the last quarter. Blue Trust Inc. purchased a new position in Cibus in the fourth quarter valued at $301,000. Finally, FineMark National Bank & Trust purchased a new position in Cibus in the third quarter valued at $300,000. 33.81% of the stock is currently owned by institutional investors and hedge funds.

Cibus Stock Performance

CBUS opened at $9.45 on Wednesday. Cibus has a one year low of $8.90 and a one year high of $24.61. The stock has a market capitalization of $203.65 million, a PE ratio of -0.51 and a beta of 1.92. The business’s 50 day moving average price is $15.19 and its 200 day moving average price is $16.98.

Cibus (NASDAQ:CBUS) last released its quarterly earnings data on Thursday, May 9th. The company reported ($1.12) EPS for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.11). Cibus had a negative net margin of 12,313.28% and a negative return on equity of 23.33%. The business had revenue of $0.55 million during the quarter, compared to analyst estimates of $0.40 million. During the same quarter in the prior year, the company posted ($5.45) earnings per share. As a group, equities research analysts forecast that Cibus will post -3.22 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $25.00 price objective on shares of Cibus in a research note on Friday, May 10th.

Cibus Company Profile

Cibus, Inc, a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases.